Fannie Mae, Freddie Mac shares tumble after conservatorship comments
Investing.com -- Sartorius Stedim (EPA:STDM) Biotech SA (DIM) on Tuesday reported sales revenue of €1,490 million for the first half of 2025, representing a 9.4% increase compared to the same period last year.
The company’s underlying EBITDA rose by 19.3% to €462 million in the first six months of the year, showing stronger profit growth than revenue expansion.
Net profit for the half-year period reached €154.1 million, according to the company’s financial report released Tuesday.
Management has confirmed its guidance for the full year 2025, maintaining its previously announced financial targets, though specific details of the outlook were not provided in the results announcement.
Sartorius Stedim Biotech, which specializes in biopharmaceutical manufacturing equipment and services, continues to show growth despite challenging market conditions in the bioprocessing sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.